HDAC9 and hematologic disorder: Vorinostat, and panobinostat, inhibitors of HDAC class I and II, are effective in patients with hematologic malignancies in phase 1 and phase 2 clinical trials [75–77] and vorinostat selectively down-regulates HDAC7 [78].